Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H25N3S |
Molecular Weight | 339.498 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CCCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CC1
InChI
InChIKey=WEYVCQFUGFRXOM-UHFFFAOYSA-N
InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/16625562Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16625562
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia. Perazine has being shown to be a potent inhibitor of human CYP1A2. It acts as a dopamine antagonist.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3356 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12523495 |
|||
Target ID: CHEMBL217 Sources: http://www.genome.jp/dbget-bin/www_bget?D01412 |
|||
Target ID: Cytochrome P450 2B, Rattus norvegicus Sources: http://www.ncbi.nlm.nih.gov/pubmed/18048963 |
45.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Taxilan Approved UseTaxilan is used in the treatment of schizophrenia |
PubMed
Title | Date | PubMed |
---|---|---|
[Electroconvulsive therapy in treatment of acute life threatening catatonia in toxic epidermal necrolysis (Lyell syndrome)]. | 1992 May |
|
Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. | 2001 Jul 1 |
|
Switching to amisulpride due to hepatic complications. | 2002 May |
|
Which neuroleptic would psychiatrists take for themselves or their relatives? | 2003 Feb |
|
Schizophrenia. | 2004 Dec |
|
Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. | 2005 Jun |
|
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography. | 2005 Nov-Dec |
|
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. | 2006 Aug |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. | 2006 Mar |
|
[Antipsychotics in clinical practice. Treatment of the first schizophrenic episode]. | 2008 Nov-Dec |
|
[Drug-induced agranulocytosis--case reports and literature review]. | 2009 |
|
Validation of derivative spectrophotometry method for determination of active ingredients from neuroleptics in pharmaceutical preparations. | 2009 Jul-Aug |
|
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. | 2010 Mar |
|
Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. | 2010 Oct 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11869638
Curator's Comment: In acutely ill and severely disturbed patients 50 mg perazine at time-intervals of 30 minutes can be administered intramuscularly
The customary dose range recommended for this antipsychotic under in-patient conditions is 75-600 mg/day (maximum 1000 mg/day).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19904008
About 80% of basal human CYP1A2 activity was reduced by the therapeutic concentrations of perazine (5-10 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05AB10
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
||
|
WHO-ATC |
N05AB10
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
||
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8042
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
84-97-9
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
Perazine
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
C81093
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
8915147A2B
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
100000079987
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
2100
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
4744
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
DTXSID6048628
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
DB12710
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697766
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
D010464
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
SUB14811MIG
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | |||
|
m8535
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
201-578-9
Created by
admin on Fri Dec 15 16:18:23 GMT 2023 , Edited by admin on Fri Dec 15 16:18:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)